Pharma major Lupin Ltd. said on Wednesday, February 25, that the Goods and Services Tax Department of Maharashtra has initiated an inspection and search at its office.
In a regulatory exchange, the company said it is cooperating with authorities and that the proceedings have no impact on its financials, operations or other activities.
The inspection sought documents related to payment of GST and claims of input tax credit.
Shares of the company ended marginally higher at ₹2,293 apiece, up 1.90% for the day.
In a separate update posted the previous day, Lupin announced that it has launched seizure medication Brivaracetam Oral Solution (10 mg/mL) in the US with approval from the US Food and Drug Administration.
US sales also helped boost sales for the quarter ended December 31, 2025. Lupin reported ₹1,175.6 crore in consolidated net profit, up 37.5% from a year earlier.
Consolidated revenue from operations came in at ₹7,167.5 crore, rising 1.7% quarter-on-quarter and 24.3% year-on-year.
